Novartis Price to Book Trend from 2010 to 2020

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>NO</div>
NVS -- USA Stock  

Report: 21st of July 2020  

Novartis Research and Development Expense is relatively stable at the moment as compared to the past year. Novartis reported last year Research and Development Expense of 9.4 Billion. As of 07/11/2020, Weighted Average Shares is likely to grow to about 2.6 B, while Gross Profit is likely to drop slightly above 32.6 B.

Search Historical Trends

 
Refresh
Check Novartis financial statements over time to gain insight into the future company performance. Apply historical fundamental analysis to find patterns among financial statement drivers such as Consolidated Income of 12.1 B, Cost of Revenue of 14.2 B or Earning Before Interest and Taxes EBIT of 14.8 B, as well as many exotic indicators such as Asset Turnover of 0.37, Book Value per Share of 29.65 or Current Ratio of 1.05. This can be a perfect complement to check Novartis Valuation or Volatility. It can also complement various Novartis Technical models. Additionally, see the analysis of Novartis Correlation with competitors.

Novartis Price to Book Marginal Breakdown

Showing smoothed Price to Book Value of Novartis AG with missing and latest data points interpolated. Measures the ratio between Market Capitalization and [EquityUSD].
ViewLast Reported 3.93 X10 Years Trend
 Price to Book Value 
      Timeline 

Novartis Price to Book Regression Statistics

Arithmetic Mean 2.71
Geometric Mean 2.66
Coefficient Of Variation 22.65
Mean Deviation 0.46
Median 2.62
Standard Deviation 0.61
Sample Variance 0.38
Range 1.96
R-Value 0.75
Mean Square Error 0.19
R-Squared 0.56
Significance 0.008483
Slope 0.14
Total Sum of Squares 3.78

Novartis Price to Book Over Time

2010  2.15 
2011  1.99 
2012  2.20 
2013  2.62 
2014  3.18 
2015  2.68 
2016  2.31 
2017  2.69 
2018  2.53 
2019  3.95 
2020  3.57 

About Novartis Financial Statement Charts

There are typically three primary documents that fall into the category of financial statements. These documents include Novartis income statement, its balance sheet, and the statement of cash flows. Novartis investors use historical funamental indicators, such as Novartis's Price to Book, to determine how well the company is positioned to perform in the future. Although Novartis investors may use each financial statement separately, they are all related. The changes in Novartis's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Novartis's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Novartis Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Novartis. Please read more on our technical analysis and fundamental analysis pages.
 2017 2018 2019 2020 (projected)
Current Assets28.21 B35.56 B29.5 B32.46 B
Total Assets133.08 B145.56 B118.37 B134.45 B

Did you try this?

Run My Watchlist Analysis Now

   

My Watchlist Analysis

Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see the analysis of Novartis Correlation with competitors. Please also try Aroon Oscillator module to analyze current equity momentum using aroon oscillator and other momentum ratios.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page